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http://dx.doi.org/10.1016/j.ccr.2014.08.001SUMMARYThe casein kinase 1A1 gene (CSNK1A1) is a putative tumor suppressor gene located in the common deleted
region for del(5q) myelodysplastic syndrome (MDS). We generated a murine model with conditional inactiva-
tion ofCsnk1a1 and found thatCsnk1a1 haploinsufficiency induces hematopoietic stem cell expansion and a
competitive repopulation advantage, whereas homozygous deletion induces hematopoietic stem cell failure.
Based on this finding, we found that heterozygous inactivation of Csnk1a1 sensitizes cells to a CSNK1 inhib-
itor relative to cells with two intact alleles. In addition, we identified recurrent somatic mutations in CSNK1A1
on the nondeleted allele of patients with del(5q) MDS. These studies demonstrate that CSNK1A1 plays a
central role in the biology of del(5q) MDS and is a promising therapeutic target.INTRODUCTION
Deletions of chromosome 5q are the most common cytogenetic
abnormalities in myelodysplastic syndrome (MDS), and patients
with isolated del(5q) have a distinct clinical phenotype (Ebert,
2011; Haase et al., 2007; Hasserjian et al., 2008). To date, no
genes within the common deleted regions (CDRs) have been
found to undergo homozygous inactivation, copy-neutral loss
of heterozygosity, or recurrent mutation (Gondek et al., 2008;
Graubert et al., 2009; Heinrichs et al., 2009; Jerez et al., 2012;
Mallo et al., 2013). Functional studies have revealed individual
genes that contribute cooperatively to the clinical phenotype
through genetic haploinsufficiency (Boultwood et al., 2010;
Chen et al., 2011; Ebert, 2011; Kumar et al., 2011; Lane et al.,
2010; Starczynowski et al., 2010). Heterozygous loss of the
RPS14 gene, for example, has been linked to impaired erythro-Significance
Our studies provide functional and genetic evidence indicatin
del(5q) MDS.We found that heterozygous inactivation ofCsnk1
activation. In addition, we found that Csnk1a1 haploinsufficien
an approach for the targeting of heterozygous deletions in canc
identified in genes within the common deleted regions of chro
subset of del(5q) MDS patients. In aggregate, these findings ind
treatment of del(5q) MDS.
Cpoiesis via p53 activation (Dutt et al., 2011; Ebert et al., 2008).
While several 5q genes have been reported to alter hematopoi-
etic stemcell (HSC) function, themechanismof clonal dominance
of del(5q) cells remains a critical unsolved question (Joslin et al.,
2007; Lane et al., 2010; Min et al., 2008; Wang et al., 2010a).
CSNK1A1 encodes casein kinase 1a (CK1a), a serine/threo-
nine kinase, and is located in the distal CDR (5q32) in del(5q)
MDS. In a careful study of gene expression in CD34+ cells from
a large cohort of del(5q) and other MDS cases, CSNK1A1 was
one of the few genes in the del(5q) CDR that has approximately
50% normal expression (Boultwood et al., 2007). Recent studies
demonstrated that CSNK1A1 is a tumor suppressor gene in
colon cancer andmelanoma, controlling proliferation by its func-
tion as a central regulator of b-catenin activity (Elyada et al.,
2011; Sinnberg et al., 2010). In hematopoiesis, stem and progen-
itor cells respond in a graded fashion to canonical Wnt/b-catening that CSNK1A1 plays a central role in the pathogenesis of
a1 causes hematopoietic stem cell expansion and b-catenin
cy sensitizes cells to casein kinase inhibition, demonstrating
er.While no recurrentlymutated genes have been previously
mosome 5q, we found recurrent mutations in CSNK1A1 in a
icate thatCSNK1A1 is a promising therapeutic target for the
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Casein Kinase 1A1 in del(5q) MDSsignaling (Luis et al., 2011). Constitutive activation of b-catenin
has been reported to increase HSC numbers followed by
apoptosis, HSC depletion, and bone marrow failure (Kirstetter
et al., 2006; Scheller et al., 2006). In contrast, less profound acti-
vation is associated with HSC expansion with enhanced repopu-
lation potential (Trowbridge et al., 2006). APC, like CK1a, is a
member of the b-catenin destruction complex and is inactivated
in approximately 95% of cases with del(5q) MDS. Mice with het-
erozygous deletion of Apc (Wang et al., 2010a) or heterozygous
for the ApcMin allele (Lane et al., 2010) have increased repopula-
tion potential in primary bone marrow transplants but decreased
repopulation potential of secondary transplants due to loss of
HSC quiescence.
We sought to explore whether haploinsufficiency or mutation
ofCsnk1a1 contributes to the biology of del(5q) MDS. In addition,
given evidence that Csnk1a1 is selectively essential for murine
MLL-AF9 leukemia cells relative to normal hematopoietic cells
(Ja¨ra˚s et al., 2014), we investigated whether CK1a is a therapeu-
tic target in del(5q) MDS.
RESULTS
Csnk1a1 Is Required for Adult Murine Hematopoiesis
To explore the role of Csnk1a1 on HSC function, we generated a
mouse model in which Csnk1a1 exon 3, essential for CK1a ki-
nase function (Bide`re et al., 2009), is flanked by loxP sites.
Following crosses to Mx1Cre transgenic mice, we induced
Csnk1a1 excision in hematopoietic cells by polyinosinic-polycy-
tidylic acid [poly(I:C)] and confirmed decreased messenger RNA
and protein expression (Figure 1A; Figure S1A available online).
We first examined whether Csnk1a1 plays a critical role in
hematopoiesis. Homozygous deletion ofCsnk1a1 in the hemato-
poietic system (Csnk1a1/Mx1Cre+) resulted in rapid lethality
5–17 days after gene excision, accompanied by a significant
decrease in all peripheral blood counts and histologic evidence
of fulminant bone marrow failure with evidence of ischemia in
multiple organs (Figures 1B–1E and S1B).
We next examined whether the observed hematologic abnor-
malities were associated with changes in hematopoietic stem
and progenitor cells (HSPCs). Ten days after Csnk1a1 excision,
Csnk1a1/Mx1Cre+ mice had a highly significant reduction of
HSCs (LSK; LinlowSca-1+ckit+), including long-term (LT; Linlow
Sca-1+ckit+CD150+CD48) and short-term (ST; LinlowSca-1+
ckit+CD150CD48)-HSCs and multipotent progenitor cells
(MPPs; LinlowSca-1+ckit+CD150-CD48+), indicating thatCsnk1a1
is essential for HSC survival (Figures 1F and S1C).
CK1a is a major regulator of p53 activity, so we investigated
whether Csnk1a1 ablation activates p53 in the bone marrow
(Elyada et al., 2011; Wu et al., 2012). Homozygous, but not het-
erozygous, Csnk1a1 deletion caused accumulation of p53 as
well as of p21, a p53 target, demonstrating that p53 is both pre-
sent and active (Figure 1G). Consistent with this finding, we
found that only complete ablation of Csnk1a1 led to significant
induction of early and late apoptoses (Figures 1H and S1D).
Csnk1a1-ablated HSCs exited quiescence and entered the cell
cycle, with a marked decrease in the number of Csnk1a1/
Mx1Cre+ HSC (LSK) in G0 and a significant increase in S/G2/M
compared to Mx1Cre+ controls (Figure 1I and Figures S1E
and S1F).510 Cancer Cell 26, 509–520, October 13, 2014 ª2014 Elsevier Inc.Csnk1a1 Loss Induces Increased b-Catenin Levels in
Both Hematopoietic and Stromal Cells
CK1a is a critical regulator of b-catenin (Cheong and Virshup,
2011). In our murine model, heterozygous and homozygous
knockout of Csnk1a1 induced strong nuclear accumulation
of b-catenin (Figure 1J). In the heterozygous knockout bone
marrow, positive staining was predominantly in hematopoietic
cells proximal to endothelial and endosteal cells, while in the ho-
mozygous knockout bone marrow, b-catenin nuclear accumula-
tion was observed in nearly all cell types, highlighting graded
b-catenin activation by Csnk1a1 gene dosage.
In addition, we observed a striking accumulation of b-catenin
in the bone marrow stroma cells of heterozygous and homozy-
gous Csnk1a1 knockout mice, consistent with the expression of
Mx1Cre in bone marrow stroma (Walkley et al., 2007). We vali-
dated this finding in mesenchymal stroma cells (MSCs) isolated
from endosteal bone (Zhu et al., 2010) and confirmed Csnk1a1
excision in the stroma (Figure S1G). We found strong b-catenin
expression in MSCs from heterozygous Csnk1a1 knockout mice
and even more pronounced expression in homozygous
knockout mice (Figure S1H). In in vitro long-term culture initi-
ating cell assays, both Csnk1a1/+Mx1Cre+ and Csnk1a1/
Mx1Cre+ MSC had significantly impaired hematopoiesis-sup-
porting capacity. Inactivation of b-catenin rescued the effect
of Csnk1a1 loss in stromal cells (Figure S1I). The hematopoietic
effects of Csnk1a1 haploinsufficiency that we found in vitro were
also observed in vivo. Eight weeks after poly(I:C) treatment, we
observed a significant reduction in bone marrow cellularity and
in the percentage of LT- and ST-HSCs in Csnk1a1/+Mx1Cre+
mice compared to Mx1Cre+ controls (Figures S1J–S1M).
Consistent with this finding, the survival of Csnk1a1/+Mx1Cre+
primary mice was significantly impaired (Figure 1B). After
15 months, Csnk1a1/+Mx1Cre+ mice developed pancytopenia,
a significant decrease in the LT-HSCs and ST-HSCs, and a
near-complete loss of myeloid progenitor cells (Figures S1N–
S1V). These results are comparable to the recently described
consequences of constitutively active b-catenin in osteoblasts
(Kode et al., 2014), although we did not observe any evidence
of malignant transformation in Csnk1a1/+Mx1Cre+ mice at
15 months.
Cell Intrinsic Csnk1a1 Ablation Leads to Bone
Marrow Failure
Having observed thatCsnk1a1 excision in primaryMx1Cre+mice
has striking effects on hematopoiesis, and given the cell-
extrinsic effects of stromal b-catenin activation on hematopoietic
cells (Kode et al., 2014; Lane et al., 2010; Stoddart et al., 2014;
Wang et al., 2010a), we examined the cell-intrinsic effects of
Csnk1a1 inactivation in hematopoietic cells using bone marrow
transplantation into wild-type (WT) recipient mice. We trans-
planted whole bone marrow cells from Csnk1a1/Mx1Cre+ or
Mx1Cre+ mice (CD45.2+) into lethally irradiated WT recipient
mice (CD45.1+). Prior to induction of Csnk1a1 excision, 4 weeks
after transplantation, more than 90% of peripheral blood cells in
recipient mice were reconstituted with donor-derived CD45.2+
cells. All recipient chimeric mice reconstituted with Csnk1a1/
Mx1Cre+ cells became moribund with bone marrow failure 8–
14 days after Csnk1a1 excision (Figure 2A; Figures S2A–S2C).
Flow cytometric analysis revealed a complete loss of HSPCs in
Figure 1. Conditional Homozygous Inactivation of Csnk1a1 Results in HSPC Ablation
(A) Deletion of Csnk1a1 in whole bone marrow cells was determined 7 days after poly(I:C) induction by quantification of Csnk1a1 transcript levels by quantitative
real-time PCR. Data are presented as remaining Csnk1a1 transcript expression in percent relative to Mx1Cre+ control mice (mean ± SD, n = 3; **p < 0.001).
(B) Kaplan-Meier survival curve ofCsnk1a1/+Mx1Cre+ (n = 10),Csnk1a1/Mx1Cre+ (n = 10), andMx1Cre+ (n = 10) control mice. Time point 0 is the day of the first
of three poly(I:C) inductions.
(C) Absolute numbers of white blood cells (WBC) and hemoglobin (Hb) levels in peripheral blood from Csnk1a1/+Mx1Cre+, Csnk1a1/Mx1Cre+, andMx1Cre+
controls 10 days after poly(I:C) induction (mean ± SD, n = 3; **p < 0.001).
(D) Numbers of whole bone marrow cells collected from tibias, femurs, and pelvis of Mx1Cre+, Csnk1a1-/+Mx1Cre+, and Csnk1a1/Mx1Cre+ 10 days after
poly(I:C) induction (mean ± SD; n = 3; *p < 0.05, **p < 0.001).
(E) Histological analysis of H&E-stained spine from Csnk1a1/+Mx1Cre+, Csnk1a1/Mx1Cre+, andMx1Cre+ controls 10 days after poly(I:C). Scale bar, 200 mm.
(F) Analysis of the HSC compartment, defined as LSK cells, LT-HSCs, ST-HSCs and MPPs, in the bone marrow (BM) from Csnk1a1/+Mx1Cre+,
Csnk1a1/Mx1Cre+, and Mx1Cre+ controls 10 days after poly(I:C) (mean ± SD, n = 5; **p < 0.001).
(G) Western blot of whole bone marrow lysate 8 days after induction of poly(I:C).
(H) Apoptosis was assessed in the LSK fraction frombonemarrowby Annexin V and 7-AAD staining (early apoptosis: Annexin V+/7-AAD; late apoptosis: Annexin
V+/7-AAD+ (mean ± SD, n = 3; *p < 0.05).
(I) Cell cycle was analyzed by combined proliferation (Ki67) and cell cycle (Hoechst 33342) staining in permeabilized LSK from bonemarrow (G0: Ki67/Hoechst;
S/G2/M: Ki67+/Hoechst+) (mean ± SD, n = 5; *p < 0.05).
(J) Immunofluorescence staining of paraffin-embedded bone marrow with an antibody against b-catenin (DAPI counterstaining). Asterisks highlight erythrocyte-
filled sinusoids. Scale bar, 20 mm.
See also Figure S1.
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tion of Csnk1a1 is essential for hematopoiesis.
In striking contrast to mice transplanted with Csnk1a1/
Mx1Cre+ cells, mice transplanted with Csnk1a1/+Mx1Cre+
had no change in survival compared to Mx1Cre+ control mice
(Figure S2A). Transplanted Csnk1a1 haploinsufficient hemato-
poietic cells fully reconstituted the bone marrow, resulting in a
normal-to-hypercellular marrow, a normal hemoglobin, and
significantly elevated white blood cell counts with lymphocytosis
(Figures 2B–2D). The lymphocytosis was caused by an increase
in T cells, consistent with reports demonstrating that moderate
Wnt activation promotes T cell differentiation (Luis et al., 2011,C2012). The percentage of Gr1+CD11b+ myeloid cells (Figure 2E)
and CD19+ B cells (Figure S2D) was not affected.
Pathological evaluation of the Csnk1a1 haploinsufficient
bone marrow revealed increased and mildly dysplastic hypo-
lobulated (micro)megakaryocytes in atypical locations, remi-
niscent of the megakaryocyte morphology in del(5q) MDS
(Figures 2F, S2E, and S2F). This phenotype was recapitulated
in vitro when whole bone marrow cells were cultured in the
presence of 10 ng/ml murine thrombopoietin. Nuclear ploidy
analysis of the CD41+ megakaryocytes revealed a shift
toward hypoploidy, consistent with hypolobation apparent in
cytospins of the cultures (Figures 2G and 2H). Over time,ancer Cell 26, 509–520, October 13, 2014 ª2014 Elsevier Inc. 511
Figure 2. Homozygous Csnk1a1 Inactivation Causes Cell-Intrinsic HSC Ablation, while Csnk1a1 Heterozygous Inactivation Causes Cell-
Intrinsic Lineage Expansion
(A) Donor chimerism (CD45.2) of Csnk1a1/+Mx1Cre+-, Csnk1a1/Mx1Cre+-, and Mx1Cre+-derived hematopoietic cells was monitored over time (mean ± SD,
n = 7).
(B) Histomorphological analysis of transplanted Csnk1a1/+Mx1Cre+ and Mx1Cre+ cells 8 weeks after poly(I:C) induction. Scale bar, 200 mm.
(C) Hemoglobin (Hb) levels were followed over time (mean ± SD, n = 7).
(D) White blood cell and lymphocyte count were monitored over time (mean ± SD, n = 7; *p < 0.05, **p < 0.001).
(E) Distribution of donor-derived (CD45.2+) myeloid cells (Gr1+/CD11b+) and T cells (CD3+) was analyzed by flow cytometry in bone marrow, spleen, and pe-
ripheral blood (mean ± SD, n = 5; *p < 0.05).
(F) Histomorphological analysis of megakaryocyte dysplasia in transplanted Mx1Cre+ and Csnk1a1/+Mx1Cre+ 8 weeks after poly(I:C) induction. Scale bar,
100 mm.
(G) Detailed megakaryocyte morphology on cytospin preparations (May-Gru¨nwald-Giemsa staining, oil immersion) Scale bar, 20 mm.
(H) Representative ploidy analysis and quantification onCD45.2+, CD41+megakaryocytes usingHoechst 33342 staining on fixed and permeabilized cells (mean ±
SD, n = 4; *p < 0.05).
(I) Platelet counts were taken over time (mean ± SD, n = 7; *p < 0.05, **p < 0.001).
See also Figure S2.
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(Figure 2I).
Haploinsufficiency of Csnk1a1 Leads to b-Catenin
Activation and Cell-Intrinsic Expansion of HSCs
CSNK1A1 has been reported to be a tumor suppressor gene in
solid tumors due to activation of b-catenin (Elyada et al., 2011;
Sinnberg et al., 2010). We first examined whether Csnk1a hap-
loinsufficiency causes a cell-intrinsic effect on the number and
function of HSCs in a noncompetitive transplantation assay.
We found an increase in the percentage of the HSC-enriched
LSK compartment, in contrast to the decrease in LSK and
Linlowckit+Sca-1 (LK) cells observed in the setting of an ab-
normal microenvironment in primary Mx1Cre+ animals (Figures
1F, S1M, and S1R). In particular, the proportion of LT-HSCs
was significantly elevated (Figure 3A).512 Cancer Cell 26, 509–520, October 13, 2014 ª2014 Elsevier Inc.To analyze whether HSC expansion might be due to exit
from quiescence and enhanced HSC proliferation, we per-
formed cell cycle analysis on HSPCs. In comparison to
CD45.2+ Mx1Cre+ control baseline hematopoiesis, CD45.2+
LSK cells and LT-HSCs from Csnk1a1/+Mx1Cre+ cells had
a significantly lower percentage of cells in the quiescent G0
fraction (in LT-HSCs but not LSK cells) and a significantly
higher percentage of cells in the cycling G1 fraction (Fig-
ure 3B) and in the S phase as seen by bromodeoxyuridine
(BrdU) incorporation (Figure S3A), consistent with exit from
quiescence.
We next examinedwhetherCsnk1a1 heterozygousHSCs have
altered b-catenin or cyclin D1 activity, as these pathways could
contribute to decreased quiescence. Csnk1a1/+Mx1Cre+
hematopoietic cells, transplanted into WT mice, had increased
nuclear b-catenin accumulation by immunohistochemistry
Figure 3. Haploinsufficiency of Csnk1a1 Leads to Cell-Intrinsic Expansion of Transplanted HSCs
(A) HSC chimerism (CD45.2) was analyzed in CD45.1 mice repopulated with Csnk1a1/+Mx1Cre+ andMx1Cre+ cells 8 weeks after induction with poly(I:C) in the
LSK cells, MPPs, LT-HSCs, and ST-HSCs (mean ± SD, n = 5; *p < 0.05).
(B) Cell cycle was analyzed by combined proliferation (Ki67) and cell cycle (Hoechst 33342) staining in permeabilized LSK cells and LT-HSCs from bone marrow
(G0: Ki67/Hoechst; S/G2/M: Ki67+/Hoechst+) (mean ± SD, n = 5; *p < 0.05, **p < 0.001).
(C) Intracellular flow cytometry for b-catenin and cyclin D1 (fluorescein isothiocyanate [FITC]-labeled secondary antibody each) on the CD45.2+ viable LSK
population (mean ± SD, n = 3; *p < 0.05).
(D) Corresponding representative flow blots to the quantitative analysis of intracellular b-catenin and cyclin D1 accumulation.
(E) Mean fluorescence intensity (MFI) of intracellular b-catenin and cyclin D1 in LSK cells (mean ± SD, n = 3; *p < 0.05).
See also Figure S3.
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We found increased b-catenin in the stem-cell-enriched LSK
fraction. b-catenin accumulation in HSCs was accompanied by
significantly increased expression of cyclin D1, a major regulator
of cell cycle progression, corroborating the G1-phase progres-
sion in the cell cycle of Csnk1a1 haploinsufficient cells. In the
lineage-positive fraction, the differences in b-catenin were not
apparent. These experiments demonstrate that heterozygous
Csnk1a1 inactivation is associated with increased levels of
b-catenin in the HSC.
As heterozygous deletion of APC occurs in approximately
95% of MDS cases and APC and CK1a are both negative
regulators of b-catenin, we analyzed the combinatorial effect
of Csnk1a1 and Apc on b-catenin levels and HSC expansion
(Figure S3F). Compound heterozygous (Csnk1a1/+Apc/+
Mx1Cre+) hematopoietic cells were transplanted into lethally
irradiated mice and analyzed over a period of 52 weeks. Com-
pound heterozygous inactivation of Csnk1a1 and Apc resulted
in significantly increased LT-HSCs, increased b-catenin levels,
and increased activation of the cell cycle in HSCs in long-term
transplants (Figures S3G–S3J). In aggregate, our data highlight
a central role for b-catenin in the pathophysiology of del(5q)
MDS.CCsnk1a1 Haploinsufficient HSCs Have Increased
Self-Renewal Ability In Vivo
As Csnk1a1 haploinsufficiency leads to a significant increase in
cycling LT-HSCs, we examined the functional capacity of
Csnk1a1 haploinsufficient cells in a competitive repopulation
assay. Four weeks after transplantation, mice were treated
with poly(I:C) to induce Csnk1a1 deletion. Csnk1a1 haploinsuffi-
cient cells outcompeted WT cells, while Mx1Cre+ control cells
were stable over time, and cells with homozygousCsnk1a1 inac-
tivation were rapidly depleted (Figure 4A).
To determine the long-term repopulating potential of Csnk1a1
haploinsufficient bone marrow, whole bone marrow cells from
the primary recipients were injected into lethally irradiated sec-
ondary and tertiary recipients. Csnk1a1 haploinsufficient bone
marrow cells had a significantly impaired response to the stress
of transplantation, resulting in significantly lower numbers of
CD45.2+ donors cells in the peripheral blood compared to
Mx1Cre+ controls each 4 weeks after secondary and tertiary
transplantation. However, 16 weeks after each round of trans-
plantation, Csnk1a1 haploinsufficient cells recovered and again
outcompeted the control cells (Figure 4A).
Having observed a competitive advantage for Csnk1a1 hap-
loinsufficient bone marrow evaluated in the peripheral blood,ancer Cell 26, 509–520, October 13, 2014 ª2014 Elsevier Inc. 513
Figure 4. Csnk1a1 Haploinsufficient HSCs Show Increased Repopulating Ability Consistent with Increased Self-Renewal
(A) Competitive repopulation assays were performed by mixing CD45.2-expressing cells (Csnk1a1/+Mx1Cre+, Csnk1a1/Mx1Cre+, or Mx1Cre+) with CD45.1
competitor cells at an approximately 50:50 ratio and transplanting the cells into lethally irradiated CD45.1 recipients. The percentage of CD45.2 donor cell
chimerism in the whole peripheral blood (PB) from peripheral blood of lethally irradiated recipient animals is shown. Time (in weeks) denotes the time relative to
termination of the poly(I:C) injections; poly(I:C) = time point 0. After 16 weeks, bone marrow was harvested and transplanted for secondary transplants, and
16 weeks later for tertiary transplants in lethally irradiated mice (mean ± SD, n = 5; *p < 0.05, **p < 0.001). tx, transplant.
(B) Donor chimerism of total bone marrow cells performed at 16 (first competitive transplant), 32 (secondary competitive transplant, 16 weeks after trans-
plantation) or 48 (tertiary competitive transplant) weeks after poly(I:C) induction (mean ± SD, n = 5; *p < 0.05).
(C and D) Donor chimerism of the HSC (LSK) (C) and progenitor cell compartments: LK; common-myeloid progenitors (CMP), LK CD34+CD16/32; granulocyte-
macrophage progenitors (GMP), LK CD34+CD16/32+; and myeloerythroid progenitors (MEP), LK CD34CD16/32 (D) performed at 16 (first competitive
transplant), 32 (secondary competitive transplant), or 48 (tertiary competitive transplant) weeks after poly(I:C) induction (mean ± SD, n = 5; *p < 0.05).
(E) Chimerism of hematopoietic lineages in the bone marrow each 16 weeks after the first, second, and third competitive transplant. Composite data of donor
(CD45.2+) granulocytes (Gr1+CD11b+), B cells (CD19+), or T cells (CD3+) are shown (mean ± SD, n = 5; *p < 0.05, **p < 0.001).
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tion (Figures 4B–4E). At both 16 weeks following the primary
transplant and 16 weeks following the secondary transplant,
Csnk1a1 haploinsufficient cells were significantly more abundant
than their WT counterparts in the percentage of LSK cells and
downstream myeloid progenitor cells, Gr1+CD11b+ myeloid
cells, and CD3+ T cells in the bone marrow.
Csnk1a1 Haploinsufficiency Sensitizes Cells to Casein
Kinase 1 Inhibition
Having demonstrated a selective advantage for cells with het-
erozygous Csnk1a1 inactivation and a severe disadvantage for514 Cancer Cell 26, 509–520, October 13, 2014 ª2014 Elsevier Inc.cells with homozygous Csnk1a1 inactivation, we postulated
thatCsnk1a1 haploinsufficiency might sensitize cells to CK1a in-
hibition. Partial inhibition of CK1a would be expected to cause
WT cells to have a phenotype similar to haploinsufficient cells,
while CK1a inhibition in cells that already have one allele inacti-
vated would approach closer to complete ablation of CK1a
activity, thereby establishing a therapeutic window for CK1a in-
hibition in del(5q) MDS cells. We tested this hypothesis using
D4476, a selective small molecule inhibitor of CK1 (Rena et al.,
2004). Since D4476 has a short half-life in vivo, we treated puri-
fied myeloid progenitors from Csnk1a1 haploinsufficient cells
and Mx1Cre+ controls with D4476 in vitro. D4476 significantly
Figure 5. Csnk1a1 Haploinsufficiency Pro-
vides a Therapeutical Window for the
Specific Treatment of Disease-Propagating
HSCs
(A) Sorted hematopoietic progenitor cells (LK)
were prestimulated for 24 hr after the sort and
treated for 72 hr with varying concentrations of
D4476. Viability of cells was analyzed after 72 hr
with the CellTiter-Glo assay, apoptosis by com-
bined Annexin V and 7AAD staining discriminating
early (Annexin V+7AAD), and late apoptosis
(AnnexinV+7AAD+) using flow cytometry (mean ±
SD, n = 5; *p < 0.05).
(B) Twenty-one days after poly(I:C) treatment,
Csnk1a1/+Mx1Cre+ or CD45.1 bone marrow was
harvested and LSK cells were sort purified. Equal
ratios of Csnk1a1/+Mx1Cre+ and CD45.1+ LSK
cells were mixed and treated for 72 hr ex vivo with
either D4476 or DMSO, followed by trans-
plantation into lethally irradiated CD45.1 mice. The
chimerismwas followed over time in the peripheral
blood (PB) (mean ± SD, n = 6; *p < 0.05, **p <
0.001).
(C) The chimerism of Csnk1a1/+Mx1Cre+ in the
bone marrow was analyzed in the LSK and pro-
genitor fractions after 12 weeks under DMSO or
D4476 treatment conditions (mean ± SD, n = 6;
**p < 0.001).
See also Figure S4.
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sufficient cells relative toMx1Cre+ controls at a range of concen-
trations, consistent with a therapeutic window for targeting
Csnk1a1 haploinsufficient cells (Figure 5A).
To assess the relative effect of D4476 treatment on HSC and
progenitor cell function in vivo, we performed a competitive repo-
pulation experiment following ex vivo exposure toD4476. Purified
LSK cells from Csnk1a1/+Mx1Cre+ (CD45.2) and WT CD45.1
mice were mixed in a 1:1 ratio and treated ex vivo with either
D4476 or DMSOcontrol for 48 hr, followed by injection of the cells
into lethally irradiatedmice. FollowingDMSO treatment,Csnk1a1
haploinsufficient cells outcompeted the WT controls, as as-
sessed by peripheral blood chimerism. In contrast, following
treatment with D4476, Csnk1a1 haploinsufficient cells were
selectively depleted. Similarly, D4476 caused a selective deple-
tion of Csnk1a1 haploinsufficient stem and progenitor cells in
the bonemarrow (Figures 5B and 5C) and reducedCsnk1a1 hap-
loinsufficient HSPCs in colony-forming unit assays (Figure S4A).
To examine if partial, systemic inhibition of CK1a would be
tolerated in a therapeutic approach targeting haploinsufficiency,
we analyzed the effects of global heterozygous Csnk1a1 inacti-
vation. Csnk1a1/+EIIaCre+ mice, in which heterozygous dele-
tion of Csnk1a1 is induced in all tissues, were born in normal
Mendelian ratios without apparent malformations. Histopatho-
logical analysis at 6 and 10 months of age revealed structural
integrity of organs, and blood counts were normal and stable
over this period of time (Figures S4B–S4D). In aggregate, these
data indicate that Csnk1a1 inhibition is an attractive therapeutic
approach for the selective targeting ofCsnk1a1 haploinsufficient
cells, such as MDS cells with del(5q).CIdentification of Recurrent SomaticCSNK1A1Mutations
in Patients with del(5q) MDS
In parallel with our functional studies, we performed whole-
exome sequencing on MDS samples to identify genetic drivers
of del(5q) MDS: genes that are selectively mutated in del(5q)
MDS or genes within the del(5q) CDRs that are recurrently so-
matically mutated in MDS cases without del(5q). We performed
whole-exome sequencing on paired samples (MDS-derived
bone marrow sample and matched normal CD3+ cells) of 21
cases: 19 del(5q) and 2 with normal karyotypes (Table S1). We
identified two cases with somatic mutations in CSNK1A1, both
in untreated cases with del(5q) withWT TP53 (Table 1). Both mu-
tations caused the same amino acid change, E98K (Figure 6A).
The mutations were confirmed to be present and somatic by
Sanger sequencing (Figure 6A). Only a fraction (75% in patient
1 and 42% in patient 2) of the nondeleted CSNK1A1 allele was
mutated. By SNP array analysis (Figure S5A), the percentage
of the del(5q) MDS clone was 70%–80% in patient 1 and 90%–
100% in patient 2. These data indicate that deletion of chromo-
some 5q occurred first and that theCSNK1A1mutation occurred
on the remaining allele of chromosome 5q. The mutation was
identified in only less than 5% of the matched control samples
from T cells. We analyzed an additional set of 22 MDS samples
with isolated del(5q) and found one additional mutation, also
altering the same codon (E98V). We examined published MDS
genome-sequencing data and found one CSNK1A1 mutation,
D140A, in a case with MDS and a normal karyotype (Graubert
et al., 2012) and CSNK1A1 D140Y in a patient with del(5q)
MDS (Woll et al., 2014). Additional CSNK1A1 mutations were
identified in the literature in other malignancies (Dulak et al.,ancer Cell 26, 509–520, October 13, 2014 ª2014 Elsevier Inc. 515
Table 1. Clinical Data of Patients with the Identified Somatic
CSNK1A1Mutations
Data #1 #2 #3
Age at diagnosis 85 82 65
Gender M F F
FAB RA RA RA
Karyotype 46,XY,del(5)
(q13q31) [17]/
46,XY[3]
46,XX,del(5)
(q13q33)[14]/
46,XX[6]
46,XX,del(5)
(q13q33)[4]/
46,XX[2]
IPSS-R 2, low risk 1, very low risk 1, very low risk
TP53 WT WT WT
Hemoglobin
(grams per deciliter)
10.6 11.8 9.5
Absolute neutrophil
count (109 per liter)
4.96 0.951 5.01
Platelets (cells per
microliter)
140,000 118,000 72,000
M, male; F, female; RA, refractory anemia; FAB, French-American-British
classification; IPSS-R, revised International Prognostic Scoring System.
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Casein Kinase 1A1 in del(5q) MDS2013; Sato et al., 2013), two of which are also missense muta-
tions of codon 98 and one of codon 140 (Figure S5B). CSNK1A1
is, therefore, a gene with recurrent somatic mutations within a
del(5q) CDR in MDS.
We tested the function of the CSNK1A1 E98V mutation by
retroviral expression of the mutant complementary DNA
(cDNA) in Csnk1a1/Mx1Cre+ hematopoietic cells, reflecting
the finding of mutations in del(5q) cells without a WT allele.
ckit+ hematopoietic cells were transduced with retroviruses ex-
pressing a WT CSNK1A1 cDNA, the CSNK1A1 E98V mutation,
or the CSNK1A1 D136N cDNA with mutational inactivation of
the CK1a kinase activity (Bide`re et al., 2009; Davidson et al.,
2005; Peters et al., 1999). Four weeks after transplantation of
transduced cells into lethally irradiated recipients, we induced
excision of both endogenousCsnk1a1 alleles. Mice transplanted
with cells expressing the kinase-dead CSNK1A1 D136N cDNA
died rapidly as expected, as the mutant cDNA was unable to
rescue the effect of the Csnk1a1 ablation (Figures S5C–S5E).
In contrast, cDNA overexpressing CSNK1A1 and CSNK1A1
E98V cDNA rescued the HSC ablation in Csnk1a1/Mx1Cre+
cells (Figures 6B and S5C). After 12 weeks, the bone marrow
of the recipient mice was fully reconstituted by cells transduced
with eitherCSNK1A1 cDNAorCSNK1A1E98V cDNA (Figure 6C).
Cells expressing CSNK1A1 or CSNK1A1 E98V reconstituted lin-
eages, as well as stem and progenitor cells (Figures 6C and S5F).
We next examined the cellular consequences of theCSNK1A1
E98V mutation. Csnk1a1/Mx1Cre+ cells transduced with
CSNK1A1 E98V cDNA, compared to cells expressing the WT
cDNA, had increased nuclear b-catenin accumulation by immu-
nofluorescence and higher b-catenin accumulation by intracel-
lular flow cytometry (Figures 6D–6F and S5G). While expression
of the kinase-dead CSNK1A1 D136N cDNA caused increased
apoptosis and HSC ablation, the CSNK1A1 E98V cDNA did
not induce p53 or apoptosis (Figures 6D, 6F, S5G, and S5H).
Furthermore, bone marrow cells expressing CSNK1A1 E98V
cDNA had an increased frequency of cells in the G1 phase of
the cell cycle, with no change in cells in G0 (Figure 6G). In aggre-516 Cancer Cell 26, 509–520, October 13, 2014 ª2014 Elsevier Inc.gate, these findings indicate that the codon 98 mutations are not
loss of function and do not cause increased p53 activation but do
increase b-catenin activity, providing a potential selective
advantage to del(5q) MDS cells.
Having demonstrated that Csnk1a1 haploinsufficient cells are
sensitized to CK1 inhibition, we tested whether CSNK1A1 E98V-
expressing cells in a Csnk1a1 null background are more sensitive
to treatment with a CK1 inhibitor than WT or Csnk1a1 haploinsuf-
ficient cells. Green-fluorescent-protein-positive (GFP+) CSNK1A1
E98V- andCSNK1A1-expressing LSK cells andCsnk1a1 haploin-
sufficient and WT LSK cells were sorted and treated with D4476
(Figure 6H). Treatment of Csnk1a1/Mx1Cre+ cells transduced
with CSNK1A1 E98V cDNA were significantly more sensitive to
the compound than Csnk1a1 haploinsufficient cells. Similar re-
sults were obtained from a coculture competition assay in the
presence of D4476 (Figures 6I and S5I).
DISCUSSION
Our studies converged on a critical role for CK1a in the patho-
genesis of del(5q) MDS. Activation of b-catenin downstream of
Csnk1a1 haploinsufficiency in a murine model, and downstream
of CSNK1A1 mutations in MDS patient samples, provides a po-
tential mechanism of clonal selection. In contrast, homozygous
inactivation of Csnk1a1 is not tolerated due to activation of
p53. The sensitivity of hematopoietic cells to Csnk1a1 gene
dosage provides a therapeutic window for targeting CK1a in
haploinsufficient cells.
In a previous study, we found Csnk1a1 to be a therapeutic
target in acute myeloid leukemia (AML) and that D4476 selec-
tively kills leukemic stem cells relative to normal HSPCs (Ja¨ra˚s
et al., 2014). Both the knockdown ofCsnk1a1 using small hairpin
RNA and the genetically engineered mouse model show that
reduction of Csnk1a1 expression by more than 50% has a nega-
tive effect on HSC expansion and survival. Haploinsufficiency, in
contrast, increases the number and function of HSCs.
b-catenin is a major driver of stem cell self-renewal and
neoplasia in multiple cellular lineages (Baba et al., 2005; Elyada
et al., 2011; Willert et al., 2003; Yeung et al., 2010). HSCs have a
graded response to b-catenin, with modest levels leading to
increased stem cell self-renewal (Baba et al., 2005) and more
marked induction leading to stem cell exhaustion (Albuquerque
et al., 2002; Kirstetter et al., 2006; Lane et al., 2010; Luis et al.,
2011). Forced expression of b-catenin, in combination with
HOXA9 and MEIS1, induces leukemia in progenitor cells (Wang
et al., 2010b), and b-catenin is essential for leukemia cells driven
by the MLL-AF9 oncogene (Miller et al., 2013). Histopathological
studies have found nuclear, nonphosphorylated b-catenin
expression in bone marrow specimen from de novo AML and
MDS patients to be a predictor for clinical outcome, and these
studies suggested an association between nuclear b-catenin
expression and del(5q) MDS, although the number of samples
studied was too small to be conclusive (Xu et al., 2008). CK1a
is a member of the b-catenin destruction complex and is, there-
fore, a known central regulator of b-catenin activity (Cheong and
Virshup, 2011). In our studies, Csnk1a1 haploinsufficiency
conferred to increased intrinsic self-renewal of HSC, with asso-
ciated nuclear b-catenin accumulation, cyclin D1 induction, and
exit from quiescence in LT-HSCs.
Figure 6. Identification and Functional Characterization of CSNK1A1 Mutations in del(5q) MDS Patients
(A) Summary of CSNK1A1 mutations identified in del(5q)MDS patients (upper panel) and Sanger sequencing results around codon 98 of the normal control
(germline) and tumors (somatic) (lower panel).
(B) Kaplan-Meier survival analysis of chimeric mice transplanted withCsnk1a1/Mx1Cre+ HSPCs expressing Csnk1a1 cDNA, Csnk1a1 D136 cDNA, or Csnk1a1
E98V cDNA. Time point 0 is the first day of poly(I:C) induction (n = 5).
(C) GFP expression in whole bone marrow (BM; left) and distribution of the different lineages (Gr1+CD11b+ neutrophils, CD3+ T cells, CD19+ B cells) in GFP+ bone
marrow cells (right) (mean ± SD, n = 3; *p < 0.05).
(D) Coimmunofluorescent staining of b-catenin and p53 in cytospin preparations of red-blood-cell-lysed whole bonemarrow cells (red, b-catenin; turquoise, p53;
green, GFP MIG vector; blue: DAPI). Scale bar, 20 mm.
(E) Quantification of b-catenin intensity using the mean fluorescence intensity (MFI) (mean ± SD, n = 3; *p < 0.05).
(F) Intracellular flow cytometry measurement of b-catenin and p53 in permeabilized whole bone marrow cells. (mean ± SD, n = 3; *p < 0.05).
(G) Cell cycle was analyzed by combined Ki67 and Hoechst 33342 staining in permeabilized whole bone marrow cells (mean ± SD, n = 3; *p < 0.05).
(H) GFP+ LSK cells from mice transplanted with either CSNK1A1 or CSNK1A1 E98V-expressing Csnk1a1/Mx1Cre+ cells as well as Csnk1a1 haploinsufficient
LSK andWT LSK cells were sort purified and exposed to vehicle, 2.5 or 10 mMD4476 for 72 hr and viability of cells was analyzed after 72 hr with the CellTiter-Glo
assay (mean ± SD, n = 5; *p < 0.05).
(I) LSK cells (all CD45.2), isolated as in (H), were treated in competition to CD45.1 WT cells in one culture well to analyze selective ablation of cells under the same
culture condition (mean ± SD, n = 5; *p < 0.05).
See also Figure S5 and Table S1.
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intrinsic effect in our study. Inactivation of Csnk1a1 in stromal
cells in our model caused stromal b-catenin levels to increase,
with consequent effects on hematopoiesis, including pancyto-
penia and HSPC depletion. This observation is consistent with
recent studies demonstrating that b-catenin accumulation in
the stroma negatively regulates HSC maintenance and might
also contribute to leukaemogenesis (Kode et al., 2014; Lane
et al., 2010).
APC, anothermember of the b-catenin destruction complex, is
also deleted in the vast majority of del(5q) MDS cases. Hemato-
poietic cells with Apc haploinsufficiency have been shown toChave enhanced repopulation potential, indicating a cell-intrinsic
gain of function in the LT-HSC population. However, in contrast
to Csnk1a1 haploinsufficiency, Apc haploinsufficient bone
marrow was unable to repopulate secondary recipients due to
loss of the quiescent HSC population (Lane et al., 2010; Wang
et al., 2010a). Different levels ofWnt activationmay explain these
findings. Similarly, deletions of Csnk1a1 and of Apc in the gut
have significantly different effects. While Csnk1a1 deletion led
to robust activation of Wnt target genes and proliferation without
invasion, Apc deletion induced immediate dysplastic transfor-
mation and rapid death (Elyada et al., 2011). CK1a has many
phosphorylation targets that could alter stem cell functionancer Cell 26, 509–520, October 13, 2014 ª2014 Elsevier Inc. 517
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Casein Kinase 1A1 in del(5q) MDS(Bide`re et al., 2009; Elyada et al., 2011; Wu et al., 2012). As has
been postulated previously, it is possible that CK1a inactivation
restrains hyperactive Wnt signaling through mechanisms yet to
be defined.
Our sequencing studies revealed recurrent mutations in a
gene located in an MDS CDR on chromosome 5q. SNP array
studies have not identified any genes on 5q that undergo homo-
zygous deletion in del(5q) MDS (Gondek et al., 2008; Graubert
et al., 2009; Heinrichs et al., 2009). Indeed, our studies would
indicate that homozygous inactivation of CSNK1A1 would be
highly deleterious to a hematopoietic cell. Although CSNK1A1
mutations in MDS are rare, they provide powerful evidence
that these lesions are genetic drivers of clonal dominance. In
functional studies, expression of the identified CSNK1A1 E98V
allele, in the setting of inactivation of both WT alleles to mimic
the genetic context of the mutations observed in patients,
caused an induction of nuclear b-catenin and a significant HSC
cell cycle progression compared to expression of the WT
CSNK1A1. Future experiments using a conditional knockin
mouse strain will be helpful to study the long-term hematopoietic
effects of the mutant allele expressed at physiological levels.
Our results indicate that CSNK1A1 is a CYCLOPS (copy num-
ber alteration yielding cancer liabilities owing to partial loss) gene
(Nijhawan et al., 2012). Heterozygous inactivation of Csnk1a1
sensitized cells to CK1 inhibition with D4476. The ablation of he-
matopoiesis in Csnka1a1 null cells and the normal-to-enhanced
hematopoiesis in Csnk1a1 haploinsufficient cells provide a
mechanistic basis for this therapeutic window. We demon-
strated that systemic Csnk1a1 haploinsufficiency in our murine
model does not have significant effects on other organs, indi-
cating that partial pharmacologic inhibition of CK1 would likely
be well tolerated. While D4476 does not have pharmacokinetic
properties for in vivo use and lacks specificity for CK1a, a
more selective compound has the potential for therapeutic utility
in the treatment of patients with myeloid malignancies associ-
ated with del(5q).
EXPERIMENTAL PROCEDURES
Generation of a Csnk1a1 Conditional Knockout Mouse
Mouse embryonic stem cells with Csnk1a1 exon 3 targeted in a C57BL/6N
genetic background were generated by the KOMP consortium (project ID:
CSD45494). The neomycin/lacZ cassette was flipped out in vitro by transfec-
tion of a plasmid expressing the flippase recombinase (FRT). Successful FRT
recombination was validated by PCR (forward primer: 50-TCGCACTTGAGC
TATTGGGGAGT-30; reverse primer: 50-AGGCATGGTAGCTCACACCTGA-30).
Following confirmation of germline transmission, mice were crossed with the
Mx1-Cremouse strain (Jackson Laboratory, stock number 002527). To excise
Csnk1a1 exon 3, Csnk1a1 conditional mice were given three rounds of 200 mg
of poly(I:C) (GE Healthcare Life Sciences) using intraperitoneal injections. Suc-
cessful excision of Csnk1a1 exon 3 was validated using forward primer
(mentioned earlier) and reverse 50AGCTGGGCTACCAAGAGGCAA-30 primer.
All experiments and procedures were conducted in the Children’s Hospital
Boston animal facility and were approved by the Children’s Hospital Institu-
tional Animal Care and Use Committee.
Flow Cytometry
Bone marrow cells were isolated by flushing and crushing pelvis and hind leg
bones with PBS (GIBCO) + 2% fetal bovine serum (FBS) + penicillin/strepto-
mycin (GIBCO). Whole bone marrow was lysed on ice with red blood cell lysis
solution (Invitrogen/Life Technologies), and washed in PBS (GIBCO) + 2%
FBS. Single-cell suspensions of spleen were prepared by pressing tissue518 Cancer Cell 26, 509–520, October 13, 2014 ª2014 Elsevier Inc.through a cell strainer followed by red blood cell lysis. Cells were labeled
with monoclonal antibodies in 2% FBS/PBS for 30 min on ice (see Supple-
mental Experimental Procedures for the information on antibodies used) and
analyzed using an LSR II flow cytometer (BD Biosciences). Apoptosis (Annexin
V APCApoptosis Detection Kit, eBioscience) and cell cycle (Ki67 cell cycle and
proliferation kit, BD Biosciences) assays were performed according to the
manufacturer’s instructions.
Bone Marrow Transplantation Assays
In transplantation assays of Csnk1a1 cells into CD45.1 WT mice, 5 3 106
freshly isolatedwhole bonemarrow cells were harvested before poly(I:C) treat-
ment and injected into the tail vein of lethally irradiated (1,050 rads) CD45.1-
positive B6.SJL (Jackson Laboratory) recipient mice without support cells. In
competitive bone marrow transplantation studies, 2 3 106 freshly isolated
bone marrow cells were harvested and transplanted via tail vein into lethally
irradiated CD45.1+ recipient mice together with 2 3 106 freshly isolated
CD45.1+ bone marrow competitor cells in an equal ratio. Four weeks after
transplantation, blood samples were taken and donor cell chimerism was
determined by flow cytometric analysis. Shortly thereafter, mice were given
three rounds of poly(I:C) treatment, and donor blood cell chimerismwas deter-
mined every 4 weeks.
Western Blots
Western blots were performed according to standard protocols. In brief, cell
lysis was performed in RIPA buffer with protease/phosphatase inhibitors. After
protein quantification, lysates were resuspended in Laemmli sample buffer
and loaded to gradient gels (Criterion Tris-HCl Gel, 8%–16%). Proteins were
transferred onto Immobilon polyvinyl difluoride membranes. As primary anti-
bodies, b-catenin (rabbit polyclonal, 9562, 1:500, Cell Signaling), p53 (mouse
monoclonal, DO-1, 1:500, Santa Cruz Biotechnology), p21 (rabbit polyclonal,
1:200, C-19, Santa Cruz Biotechnology), cyclin D1 (rabbit monoclonal,
1:200, SP4, Thermo Fisher Scientific), and GAPDH (rabbit polyclonal,
1:4000, Bethyl Laboratories) were applied.
Histopathology
For histological and immunohistochemical analyses, murine organs were fixed
in 3.7% formaldehyde overnight, dehydrated, and prepared for paraffin
embedding. Hematoxylin and eosin (H&E) staining was performed according
to routine protocols. For immunohistochemical stainings, the avidin-biotin
complex was applied. Peripheral blood smears were stained with May-Gru¨n-
wald-Giemsa (Sigma-Aldrich). Images were obtained on a Nikon Eclipse E400
microscope equipped with a SPOT RT color digital camera (model 2.1.1, Diag-
nostic Instruments).
Viral Vector Cloning
MIG-CSNK1A1, MIG-CSNK1A1(E98V), and MIG-CSNK1A1(D136N) were
flanked by Not1 and Xho1 sites for convenient cloning into the MIG vector
backbone.
Patient Samples and Sequencing
Patients included in the whole-exome sequencing were diagnosed between
2008 and 2013 at different Spanish hospitals affiliated with the MDS Spanish
Group (Grupo Espan˜ol de SMD, GESMD). Patients were diagnosed with
MDS according to the French-American-British and 2008 World Health Orga-
nization classifications. Samples were deidentified at the time of inclusion. This
study was approved by institutional review boards (Clinical Research Ethics
Committee Institut Catala` de la Salut/Germans Trias i Pujol Hospital and Clin-
ical and Ethics Committee Parc de Salut MAR) and performed in accordance
with the Declaration of Helsinki. All patients gave their informed written con-
sent. Whole-exome sequencing was performed using paired-end reads gener-
ated fromDNA libraries prepared fromMDSsamples (whole bonemarrow) with
matched normal samples (CD3+ lymphocytes isolated from peripheral blood).
Whole-exome hybrid capture was carried out on 3 mg of genomic DNA using
the SureSelect Human Exome Kit version 3 (Agilent Technologies). The
captured exome library was sequenced with 100 base-pair (bp) paired-end
reads on an Illumina HiSeq2000 platform (Illumina). Whole-exome sequencing
data were analyzed using an in-house bioinformatics pipeline as previously re-
ported elsewhere (BWA;GATK’s; VarScan2; SAMTools; SnpEff: (Koboldt et al.,
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Casein Kinase 1A1 in del(5q) MDS2012; McKenna et al., 2010). Somatic mutations identified as alterations pre-
sent in tumor but not in the matched CD3+ sample were validated by Sanger
sequencing. Sanger sequencing was performed on genomic DNA isolated
from whole bone marrow cells and CD3+ cells using the GentraPuregene
Cell kit (QIAGEN). Exon 3 from CSNK1A1 gene was amplified by PCR using
the following primers: forward primer: 50-TCCTTTTGTTTCGTTAGGTGGT-30
and reverse primer 50-AAGGTTAAATAGTGATGCACAGGA-30; amplification
size, 251 bp). SNP arrays were performed with the Genome-Wide Human
SNPArray 6.0 fromAffymetrix. Assayswere performed according to Affymetrix
protocols.
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for SNP arrays is
GSE59244.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.ccr.2014.08.001.
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